Furthermore, CCL5 positivity in ICs was associated with a 1.93-fold, 1.87-fold, 3.52-fold, and 2.21-fold increased risk of tumor-associated death for patients with tumor stage pT3 + 4, nodal stage N0, nodal stage NX, or no chemotherapy, respectively. This evidence concerns the gene CCL5 and neoplasm.